Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to significant regulatory, supply and competitive barriers to entry with respect to Actimmune; (iii) risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (iv) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the ASCEND phase 3 clinical trial may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (v) risks related to unexpected regulatory actions or delays or government regulation generally; (vi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (vii) government, industry and general public pricing pressures; and (viii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.inter
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... ... August 25, 2015 , ... A new ... cancerous is described by University of Illinois researchers in the Journal of ... , In “ Breast cancer diagnosis using spatial light interference microscopy ,” published ...
(Date:8/25/2015)... ... August 25, 2015 , ... One of the world’s ... Resilinc Corp., Bindiya Vakil, has been on a mission for the past two ... global supply chain operations - from the two massive explosions that occurred on August ...
(Date:8/25/2015)... Aug. 25, 2015 Doximity, the leading ... physicians, today launched its second annual Residency ... the next generation of doctors research and compare ... percent of all senior medical students used Doximity ... as new physicians. The new Residency Navigator brings ...
(Date:8/25/2015)... , Aug. 25, 2015 MitoQ Ltd, ... launched the latest addition to the brand,s growing ... a comprehensive and highly targeted variation of MitoQ,s ... blood sugar and insulin levels, weight management and ... ingredient in MitoQ, was developed at Otago University, ...
Breaking Biology Technology:New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3MitoQ Launches Revolutionary NZ-Developed Supplement to Support Blood Sugar Balance 2MitoQ Launches Revolutionary NZ-Developed Supplement to Support Blood Sugar Balance 3MitoQ Launches Revolutionary NZ-Developed Supplement to Support Blood Sugar Balance 4
... News Facts, , ... life sciences industry -- including,biopharmaceutical companies, contract ... increasingly turning to Oracle(R) Remote,Data Capture (RDC) ... effectively. , , -- ...
... Mealey,s Conferences (now HB,Litigation Conferences) released its upcoming schedule ... for women in the legal profession. , , ... 22 - Asbestos Gaskets: Exposure and the State of the ... , February 5 - Nanotechnology: ...
... Jan. 20 Amgen (Nasdaq: AMGN ) today ... full year financial results on Monday, Jan. 26, 2009 after ... followed by a conference call with the investment community at ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
Cached Biology Technology:Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection 2Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection 3Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection 4Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences 2Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results 2
(Date:8/26/2015)... , August 26, 2015 The ... and Five Factor), Application (Travel & Immigration, Government, Banking, ... Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication ... 2020, growing at a CAGR of 17.7% between 2015 ... 82 F igures spread through 169 ...
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/24/2015)... TOWN, South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and ... with the "2015 African Biometrics Company of the Year ... in Nigeria .   -Cross ... and http://www.presseportal.de/nr/8896 - On Thursday evening, ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... at Rutgers University studying the cause of a rare ... adolescence say new findings may provide clues to understanding ... developing better tools to treat them. In today,s ... Herrup, Ronald Hart and Jiali Li in the Department ...
... University of Miami Miller School of Medicine researchers played ... genetics collaboration to date, which identified 11 new regions ... doubling the number of potential genetics-based therapeutic targets to ... the study gives a broader view of the genetic ...
... specific neural cell types are essential for studies ... Culturing Neural Cells: A Laboratory Manual provides step-by-step ... tissues and culturing them under conditions that closely ... detail how to dissect the brain, spinal cord, ...
Cached Biology News:Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 2Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 3International collaboration finds 11 new Alzheimer's genes to target for drug discovery 2
Applications: Western blotting ...
... entry by collecting data from any RS232 ... Collect is extremely easy to use and ... entry. An excellent solution for collecting ... force gauges, digital calipers, bar code readers, ...
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: